Clinical Trial Update: [18F]PI-2620 Phase 3 Histopathological Study [Phase 3]

View source ↗

Summary

A Phase 3 histopathological study of the PET tracer [18F]PI-2620 for Alzheimer's disease is currently recruiting, sponsored by Life Molecular Imaging Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F]PI-2620 (PI-2620)

Snippet

Sponsor: Life Molecular Imaging Ltd | Conditions: Alzheimer Disease | Phase 3 | Status: RECRUITING